IUI1 Stock Chart & Stats
€320.35
-€7.60(-2.37%)
At close: 4:00 PM EDT
€320.35
-€7.60(-2.37%)
Day’s Range― - ―
52-Week Range€290.45 - €516.10
Previous CloseN/A
Volume498.00
Average Volume (3M)404.00
Market Cap
€134.82B
Enterprise Value€136.97B
Total Cash (Recent Filing)€5.22B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)47.7
Beta0.64
Next Earnings
Oct 20, 2026EPS Estimate
2.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.85
Shares Outstanding353,278,050
10 Day Avg. Volume312
30 Day Avg. Volume404
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)11.34
Price to Sales (P/S)20.08
P/FCF Ratio81.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€440.69Price Target Upside37.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)9.64
Revenue Forecast (FY)€10.49B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelThe large recurring share of revenue reflects the durability of Intuitive’s installed-base model, where procedures generate repeat instrument and service purchases. This provides revenue visibility, supports customer lifetime economics, and reduces reliance on periodic system placements alone.
Installed Base ExpansionContinued expansion of the installed base strengthens Intuitive’s competitive position and creates a broader foundation for future procedures, instruments, accessories, and service revenue. A larger footprint also deepens customer familiarity and supports adoption across specialties and care settings.
Strong Cash GenerationStrong free cash flow gives Intuitive substantial capacity to fund research, product development, training, and commercial expansion internally. High cash conversion and a conservative balance sheet also provide resilience while preserving flexibility for shareholder returns and strategic investment.
Bears Say
China Market PressureChina presents a structural challenge because weaker tenders, rising domestic competition, and pricing pressure can limit system placements and reduce revenue growth in an important market. The fact that da Vinci 5 is not yet cleared there may further constrain product momentum.
Growth DecelerationSlower growth reduces the pace at which Intuitive can expand its installed base and compound procedure-driven recurring revenue. Although profitability remains strong, a maturing core business makes sustained innovation, new indications, and geographic expansion increasingly important to future growth.
Instrument Revenue PressureThe extended-use instrument program could improve customer economics and support adoption, but it may also weaken the recurring revenue yield from each benign procedure. If broadly adopted, lower replacement frequency could pressure instruments-and-accessories growth and alter the business model’s economics.
Intuitive Surgical News
IUI1 FAQ
What was Intuitive Surgical’s price range in the past 12 months?
Intuitive Surgical lowest stock price was €290.45 and its highest was €516.10 in the past 12 months.
What is Intuitive Surgical’s market cap?
Intuitive Surgical’s market cap is €134.82B.
When is Intuitive Surgical’s upcoming earnings report date?
Intuitive Surgical’s upcoming earnings report date is Oct 20, 2026 which is in 6 days.
How were Intuitive Surgical’s earnings last quarter?
Intuitive Surgical released its earnings results on Jul 16, 2026. The company reported €2.499 earnings per share for the quarter, beating the consensus estimate of €2.241 by €0.258.
Is Intuitive Surgical overvalued?
According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued.
Does Intuitive Surgical pay dividends?
Intuitive Surgical does not currently pay dividends.
What is Intuitive Surgical’s EPS estimate?
Intuitive Surgical’s EPS estimate is 2.36.
How many shares outstanding does Intuitive Surgical have?
Intuitive Surgical has 353,278,050 shares outstanding.
What happened to Intuitive Surgical’s price movement after its last earnings report?
Intuitive Surgical reported an EPS of €2.499 in its last earnings report, beating expectations of €2.241. Following the earnings report the stock price went down -12.252%.
Which hedge fund is a major shareholder of Intuitive Surgical?
Currently, no hedge funds are holding shares in DE:IUI1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intuitive Surgical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€440.69 (37.57% Upside)
€440.69 (37.57% Upside)
Blogger Sentiment
Bullish
DE:IUI1 Sentiment 84%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.13%
12-Months-Change
Fundamentals
Return on Equity
17.83%
Trailing 12-Months
Asset Growth
3.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Intuitive Surgical
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
IUI1 Company Deck
IUI1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: robust revenue (+19%), strong profitability (42% non-GAAP operating margin), healthy procedure growth (total +16%) and capital placements (468 da Vinci systems), plus strong cash flow. The company also highlighted meaningful product progress (da Vinci 5 updates, SP and XiR momentum, ION adoption) and clinical evidence supporting adoption. Key risks were noted but were mostly market- and policy-driven (U.S. patient coverage dynamics, China tender and pricing pressure), some procedure-mix headwinds (bariatrics) and an unquantified impact from the extended-use instrument program. Overall, the positive metrics and growth drivers materially outweigh the challenges discussed.View all DE:IUI1 earnings summariesIUI1 Revenue Breakdown
67.72% U.S.
32.28% Outside of U.S
IUI1 Stock 12 Month Forecast
Average Price Target
€440.69
▲(37.57% Upside)